
    
      This will be a multi-center, global, open-label study in adult suffering from fluctuating
      Parkinson's disease subjects who have successfully completed the core study IN 11 004.

      After signing informed consent and meeting inclusion/exclusion criteria, eligible subjects
      will be enrolled into a 12-month open-label extension and receive the AP-CD/LD as needed.

      Efficacy and safety will be assessed throughout the study period.
    
  